The goal of this clinical trial is to learn about the effect of vitamin D in patients with prophylactic therapy for episodic and chronic tension-type headache in amitriptyline or topiramate treatment. The main question it aims to answer are:

• What is the effect of vitamin D in patients with prophylactic therapy for episodic and chronic tension-type headache?

Patients will have the next selection criteria:

• Patients diagnosed by a neurologist in the headache clinic
• Criteria for episodic and chronic tension-type headache
• Poor clinical response to prophylactic treatment (amitriptyline, topiramate)
• Use of at least 1 prophylactic medication or a history of having used them.
• Onset of disease between the ages of 18 and 60
• Signature of informed consent

The population will be randomly divided into the following 3 treatment groups:

• Participants amitriptyline or topiramate treatment.
• Patients with placebo (Calcium) + topiramate/amitriptyline,
• Participants with vitamin D3/calcium+topiramate/amitriptyline. Researchers will compare the groups to see if vitamin D can decrease the intensity of your headache and therefore have a new therapeutic option.

It will be a 4 month study. Each month a package containing treatment will be delivered, which may be conventional medication or tablets with conventional medication added with vitamins.

Inclusion Criteria:

• Patients diagnosed by a neurologist in the headache clinic
• Criteria for episodic and chronic tension-type headache
• Poor clinical response to prophylactic treatment (amitriptyline, topiramate)
• Use of at least 1 prophylactic medication or a history of having used them.
• Onset of disease between the ages of 18 and 60
• Signature of informed consent

Exclusion Criteria:

• Patients with secondary headache (cranioencephalic trauma, cerebral infarction)
• Patients with primary headache other than tension headache
• Suffer heart, liver, and kidney diseases.
• Medications: thiazides
• Pregnant women
• They do not want to participate

Each month the treatment will be given in equal bottles that will be marked on the label with a color (red, blue, green), the green color corresponding to placebo, red to vitamin D3+calcium and blue to calcium, only the doctors in charge of applying the questionnaires will know the group to which each patient belongs, in this way the double blind is not broken.

The placebo will be used to evaluate the effect that produced the feeling of being benefited from a new treatment, the foregoing to avoid bias and have greater reliability of the results, when compared with the gold standard.